Genzyme cutting jobs at newly-acquired Bone Care

Just weeks after completing a deal to buy Bone Care International for $719 million, Genzyme announced it will hand out pink slips to about 40 employees. Most of the workers had been employed in various administrative duties. Genzyme says it plans to retain Bone Care's laboratory facility and most of its scientists. Bone Care sold a drug that restores kidney patients' vitamin D levels.

- read this report in the Milwaukee Journal-Sentinel for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.